enVVeno Medical Corporation Price & Performance (NVNO)

enVVeno Medical’s VenoValve is being highlighted at the 47th Annual Charing Cross Symposium in London, with Dr. David Dexter presenting clinical progress and future prospects. The device, positioned as a first-in-class surgical solution for severe deep venous CVI, awaits an FDA decision on its pre-market application in the second half of 2025.12

Recent trial results for enVVeno Medical’s VenoValve show 78% of patients maintained significant benefits at two years, including 75% pain reduction. With 2.5 million potential new U.S. patients annually, the company is positioned for growth pending FDA approval, expected later this year. Financials indicate sufficient cash through key milestones.34

enVVeno Medical’s stock has experienced notable swings, rising 7.85% on April 22, but remains within a broad, downward trend. Technical analysis points to continued volatility and high risk until clearer signals emerge, with investors awaiting the FDA’s decision on VenoValve in the coming months.53